Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Non-Current Debt (2021 - 2022)

Fennec Pharmaceuticals filings provide 2 years of Non-Current Debt readings, the most recent being $25.0 million for Q3 2022.

  • On a quarterly basis, Non-Current Debt changed N/A to $25.0 million in Q3 2022 year-over-year; TTM through Sep 2022 was $25.0 million, a N/A change, with the full-year FY2021 number at $5.0 million, changed N/A from a year prior.
  • Non-Current Debt hit $25.0 million in Q3 2022 for Fennec Pharmaceuticals, up from $4.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $25.0 million in Q3 2022 to a low of $4.0 million in Q2 2022.